These are the stocks posting the largest moves before the bell.Market Insiderread more
Treasury Secretary Steven Mnuchin says if the call goes well, he would expect in-person meetings to take place.Marketsread more
Netflix shares are cratering after it missed Wall Street's target for international subscriber growth.Investingread more
Toys R Us is opening two permanent stores in November — at Simon Property Group's Galleria mall in Houston and at Unibail-Rodamco-Westfield's Garden State Plaza mall in...Retailread more
Netflix blamed its content slate, regional price increases and a 'pull-forward effect' of its strong Q1 growth for the miss.Technologyread more
Billionaire hedge fund manager Ray Dalio just picked gold as a prime long-term opportunity. Here's why one market watcher says he could be wrong.Trading Nationread more
Revenue of $10.24 billion exceeded the consensus estimate by almost $250 million.Financeread more
The pace of companies moving production out of China is accelerating, according to the Nikkei Asian review.Marketsread more
Raymond James upgraded Apple and said its most recent checks show Apple is preparing to bring a 5G iPhone to a wider range of models than previously thought.Marketsread more
Despite a disappointing earnings report, Wall Street analysts are sticking by the stock and looking ahead to the third quarter.Marketsread more
FaceApp, the viral app that makes you look old and has been at the center of privacy concerns, now warns you it uploads your picture.Technologyread more
LONDON, June 17 (Reuters) - Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.
Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure.
"In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made," he said in an interview.
"Now what we do is we pick five or six programs, and concentrate investment there."
GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments.
In today's market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates.
"Rather than do things sequentially, you do them in parallel, or as close to parallel as possible," Miels said.
GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK'916 against multiple myeloma, a common and incurable type of blood cancer.
Likewise, GSK doubled down on its quest to bring a drug known as GSK'165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading.
"This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds," Miels said.
More trials will be run to make the pain argument more clearly, he added.
GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments.
Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible.
At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market. (Reporting by Ludwig Burger; Editing by Mark Potter)